ASP Isotopes (NASDAQ:ASPI) Stock Price Up 12.1% – Time to Buy?

ASP Isotopes Inc. (NASDAQ:ASPI) rose 12.1% during mid-day trading on Monday . The stock traded as high as $5.96 and last traded at $6.0310. Approximately 3,404,655 shares changed hands during trading, a decline of 31% from the average daily volume of 4,923,636 shares. The stock had previously closed at $5.38.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a research note on Friday, March 27th. Canaccord Genuity Group reissued a “buy” rating and set a $11.00 price target on shares of ASP Isotopes in a report on Tuesday, April 14th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, ASP Isotopes has an average rating of “Hold” and an average target price of $13.00.

ASP Isotopes Trading Up 15.6%

The company has a current ratio of 12.23, a quick ratio of 12.20 and a debt-to-equity ratio of 0.77. The firm has a 50-day moving average price of $5.04 and a 200-day moving average price of $6.26. The company has a market capitalization of $783.10 million, a price-to-earnings ratio of -2.91 and a beta of 3.26.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings data on Friday, April 10th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.70). ASP Isotopes had a negative net margin of 734.14% and a negative return on equity of 161.55%. The firm had revenue of $33.32 million during the quarter, compared to analyst estimates of $2.03 million.

Insider Buying and Selling at ASP Isotopes

In other news, COO Robert Ainscow sold 22,500 shares of the firm’s stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $5.21, for a total transaction of $117,225.00. Following the completion of the transaction, the chief operating officer owned 1,490,317 shares in the company, valued at approximately $7,764,551.57. This trade represents a 1.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Duncan Moore sold 11,642 shares of ASP Isotopes stock in a transaction that occurred on Thursday, April 16th. The stock was sold at an average price of $5.21, for a total transaction of $60,654.82. Following the completion of the transaction, the director directly owned 1,044,928 shares in the company, valued at $5,444,074.88. This represents a 1.10% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 90,704 shares of company stock valued at $463,252. 14.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP bought a new position in shares of ASP Isotopes in the third quarter valued at $34,000. BNP Paribas Financial Markets boosted its stake in shares of ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after acquiring an additional 2,548 shares in the last quarter. Close Asset Management Ltd acquired a new position in shares of ASP Isotopes in the 3rd quarter worth $72,000. Legal & General Group Plc grew its holdings in shares of ASP Isotopes by 30.4% in the 3rd quarter. Legal & General Group Plc now owns 8,377 shares of the company’s stock worth $81,000 after acquiring an additional 1,953 shares during the last quarter. Finally, IFP Advisors Inc acquired a new stake in shares of ASP Isotopes during the fourth quarter worth $48,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.